Altretaminum [Inn-Latin] en es it fr

Altretaminum [Inn-Latin] Brand names, Altretaminum [Inn-Latin] Analogs

Altretaminum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Altretaminum [Inn-Latin] Chemical_Formula


Altretaminum [Inn-Latin] RX_link

Altretaminum [Inn-Latin] fda sheet

Altretaminum [Inn-Latin] msds (material safety sheet)

Altretaminum [Inn-Latin] Synthesis Reference

No information avaliable

Altretaminum [Inn-Latin] Molecular Weight

210.28 g/mol

Altretaminum [Inn-Latin] Melting Point

172-174 oC

Altretaminum [Inn-Latin] H2O Solubility

91 mg/L

Altretaminum [Inn-Latin] State


Altretaminum [Inn-Latin] LogP


Altretaminum [Inn-Latin] Dosage Forms


Altretaminum [Inn-Latin] Indication

For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.

Altretaminum [Inn-Latin] Pharmacology

Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine and its metabolitics have been negative. Altretamine has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement of cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.

Altretaminum [Inn-Latin] Absorption

No information avaliable

Altretaminum [Inn-Latin] side effects and Toxicity

No information avaliable

Altretaminum [Inn-Latin] Patient Information

No information avaliable

Altretaminum [Inn-Latin] Organisms Affected

Humans and other mammals